Market closedADR

Opthea/$OPT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Opthea

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Ticker

$OPT
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology

Headquarters

South Yarra, Australia

Employees

33
Website
opthea.com

Opthea Metrics

BasicAdvanced
$571M
-
-$0.35
1.61
-

$571M

1.61

$4.98

$1.79

13K

2.938

2.877

-264.524

-264.647

-6.34%

-83.43%

539.39%

8,719.512

-10.8

-10.8

-14.167

-32.03%

7.17%

39.93%

34.60%

What the Analysts think about Opthea

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Opthea stock.

Opthea Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Opthea Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Opthea News

AllArticlesVideos
Opthea to Host Investor Days in New York and Australia

Opthea to Host Investor Days in New York and Australia

GlobeNewsWire·7 days ago
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·4 weeks ago
Opthea's Wet AMD Program to be Featured at FLORetina 2024

Opthea's Wet AMD Program to be Featured at FLORetina 2024

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OPT

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Opthea stock?

Opthea (OPT) has a market cap of $571M as of January 15, 2025.

What is the P/E ratio for Opthea stock?

The price to earnings (P/E) ratio for Opthea (OPT) stock is 0 as of January 15, 2025.

Does Opthea stock pay dividends?

No, Opthea (OPT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Opthea dividend payment date?

Opthea (OPT) stock does not pay dividends to its shareholders.

What is the beta indicator for Opthea?

Opthea (OPT) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.